CL
ACAD icon

Choreo LLC’s Acadia Pharmaceuticals ACAD Stock Holding History

Choreo LLC’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$686K Buy
27,134
+4,244
+19% +$93.4K 0.01% 815
2026
Q1 		$510K Sell
22,890
-296
-1% -$7.07K 0.01% 928
2025
Q4 		$619K Buy
+23,186
New +$554K 0.01% 824

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Choreo LLC's ACAD Position: Q2 2026 in Review

Choreo LLC increased its Acadia Pharmaceuticals (ACAD) stake by 19% in Q2 2026, buying an estimated $93.4K and bringing the position to 27,134 shares worth $686K. The position accounts for 0.01% of the portfolio, ranked #815.

Choreo LLC first reported a position in ACAD in Q4 2025 and has held it in 3 quarters since. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Choreo LLC held 27,134 shares of Acadia Pharmaceuticals worth $686K as of Q2 2026.
  • Choreo LLC bought 4,244 Acadia Pharmaceuticals shares in Q2 2026, an estimated $93.4K.
  • Acadia Pharmaceuticals made up 0.01% of Choreo LLC's portfolio in Q2 2026, its #815 holding.
  • Choreo LLC first reported a position in Acadia Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Choreo LLC's 13F filing for Q2 2026, filed 4 Aug 2026.